HAP Trading’s Juno Therapeutics, Inc. JUNO Stock Holding History

HAP Trading’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-10,800	Closed	-$79K	–	1382
2016 Q4	$79K	Buy	+10,800	New	+$264K	﹤0.01%	597
2015 Q4	–	Sell	-112,900	Closed	-$1.77M	–	1227
2015 Q3	$1.77M	Buy	112,900 +33,600	+42%	+$1.47M	0.09%	198
2015 Q2	$1.04M	Buy	+79,300	New	+$4.21M	0.06%	256

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

HAP Trading's JUNO Position: Q1 2017 in Review

HAP Trading sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2017, closing a stake of 10,741 shares — an estimated $202K sold.

HAP Trading first reported a position in JUNO in Q2 2015 and held it in 3 quarters. The position peaked at $880K in Q2 2015. 157 funds tracked by Wall St. Rank hold JUNO as of Q1 2017.

HAP Trading reported no remaining Juno Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
HAP Trading sold 10,741 Juno Therapeutics, Inc. shares in Q1 2017, an estimated $202K.
HAP Trading first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 3 quarters.
HAP Trading's Juno Therapeutics, Inc. position peaked at $880K in Q2 2015.
157 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2017.

Based on HAP Trading's 13F filing for Q1 2017, filed 12 May 2017.